Treace Medical Concepts (TMCI) Cost of Revenue (2020 - 2026)

Treace Medical Concepts has reported Cost of Revenue for 7 years, with the latest figure at $9.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 72.89% year-over-year to $9.8 million; the trailing twelve-month figure through Mar 2026 stood at $16.6 million (down 92.66% YoY), and the FY2025 full-year result was $42.9 million, down 70.92% from the prior year.
• Cost of Revenue for Q1 2026 stood at $9.8 million, up from -$60.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $119.8 million in Q4 2024, with the low at -$65.8 million in Q4 2023.
• Historically, Cost of Revenue has averaged $16.9 million across 5 years, with a median of $26.6 million in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 574.7% — and 2025, when it plunged 150.67%.
• Treace Medical Concepts' Cost of Revenue stood at -$48.9 million in 2022, then sank by 34.41% to -$65.8 million in 2023, then soared by 282.07% to $119.8 million in 2024, then tumbled by 150.67% to -$60.7 million in 2025, then jumped by 116.13% to $9.8 million in 2026.
• The last three Cost of Revenue figures came in at $9.8 million (Q1 2026), -$60.7 million (Q4 2025), and $34.4 million (Q3 2025), per Business Quant data.